JP2021527053A5 - - Google Patents
Info
- Publication number
- JP2021527053A5 JP2021527053A5 JP2020567857A JP2020567857A JP2021527053A5 JP 2021527053 A5 JP2021527053 A5 JP 2021527053A5 JP 2020567857 A JP2020567857 A JP 2020567857A JP 2020567857 A JP2020567857 A JP 2020567857A JP 2021527053 A5 JP2021527053 A5 JP 2021527053A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pharmaceutically acceptable
- carboxylic acid
- acceptable salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862681913P | 2018-06-07 | 2018-06-07 | |
| US62/681,913 | 2018-06-07 | ||
| PCT/US2019/035934 WO2019236938A1 (en) | 2018-06-07 | 2019-06-07 | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527053A JP2021527053A (ja) | 2021-10-11 |
| JP2021527053A5 true JP2021527053A5 (cg-RX-API-DMAC10.html) | 2022-06-14 |
| JP7387179B2 JP7387179B2 (ja) | 2023-11-28 |
Family
ID=68765508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567857A Active JP7387179B2 (ja) | 2018-06-07 | 2019-06-07 | 発達障害の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸および関連化合物、(1s,3s)-3-アミノ-4-(ジフルオロメチリデン)シクロペンタン-1-カルボン酸ならびにビガバトリンの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10813899B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3813816B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7387179B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102744830B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN112770739B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019280980B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3102786A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2948263T3 (cg-RX-API-DMAC10.html) |
| IL (2) | IL279220B2 (cg-RX-API-DMAC10.html) |
| MX (2) | MX2020013290A (cg-RX-API-DMAC10.html) |
| PL (1) | PL3813816T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019236938A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019236938A1 (en) | 2018-06-07 | 2019-12-12 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
| WO2020039262A1 (en) | 2018-08-18 | 2020-02-27 | Ftf Pharma Private Limited | Pharmaceuticals solution for oral dosage |
| WO2024058812A1 (en) | 2022-09-16 | 2024-03-21 | Pyros Pharmaceuticals, Inc. | Vigabatrin liquid pharmaceutical composition |
| IL322802A (en) | 2023-02-17 | 2025-10-01 | Ovid Therapeutics Inc | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of gastrointestinal disorders and as an immunomodulatory agent |
| US20240285565A1 (en) | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
| US20260130878A1 (en) * | 2024-11-12 | 2026-05-14 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| WO2005120496A2 (en) | 2004-05-24 | 2005-12-22 | Regents Of The University Of California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
| WO2009033818A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| CA2790820A1 (en) | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US20130230586A1 (en) | 2010-10-02 | 2013-09-05 | Link Research & Grants Corporation | Treatment of Tinnitus and Related Auditory Dysfunctions |
| WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| WO2013112363A1 (en) | 2012-01-27 | 2013-08-01 | Catalyst Pharmaceutical Partners | Method of treating tourette's disorder with gaba-aminotransferase inactivators |
| TW201606304A (zh) * | 2013-09-09 | 2016-02-16 | 亞克柏拉有限公司 | 測定治療反應之方法 |
| US20150224164A1 (en) | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| AU2015342801A1 (en) | 2014-11-07 | 2017-05-18 | Hadasit Medical Research Services And Development Ltd. | Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma |
| US20170348232A1 (en) * | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| CN108137484B (zh) * | 2015-10-09 | 2021-02-12 | 西北大学 | 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物 |
| US10632088B2 (en) | 2016-10-10 | 2020-04-28 | Northwestern University | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria |
| KR20240110989A (ko) * | 2017-02-08 | 2024-07-16 | 오비드 테라퓨틱스 인크. | 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들 |
| US20200268711A1 (en) * | 2017-11-14 | 2020-08-27 | Sk Biopharmaceuticals Co., Ltd. | Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome |
| JP7475055B2 (ja) | 2018-05-25 | 2024-04-26 | ノースウェスタン ユニバーシティ | (s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸の合成法 |
| WO2019236938A1 (en) | 2018-06-07 | 2019-12-12 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
-
2019
- 2019-06-07 WO PCT/US2019/035934 patent/WO2019236938A1/en not_active Ceased
- 2019-06-07 CN CN201980052607.5A patent/CN112770739B/zh active Active
- 2019-06-07 EP EP19815892.5A patent/EP3813816B1/en active Active
- 2019-06-07 IL IL279220A patent/IL279220B2/en unknown
- 2019-06-07 AU AU2019280980A patent/AU2019280980B2/en active Active
- 2019-06-07 IL IL304270A patent/IL304270B2/en unknown
- 2019-06-07 CA CA3102786A patent/CA3102786A1/en active Pending
- 2019-06-07 MX MX2020013290A patent/MX2020013290A/es unknown
- 2019-06-07 US US16/434,300 patent/US10813899B2/en active Active
- 2019-06-07 PL PL19815892.5T patent/PL3813816T3/pl unknown
- 2019-06-07 KR KR1020217000541A patent/KR102744830B1/ko active Active
- 2019-06-07 JP JP2020567857A patent/JP7387179B2/ja active Active
- 2019-06-07 ES ES19815892T patent/ES2948263T3/es active Active
-
2020
- 2020-10-16 US US17/072,511 patent/US11660277B2/en active Active
- 2020-12-07 MX MX2023006497A patent/MX2023006497A/es unknown
-
2023
- 2023-04-19 US US18/302,997 patent/US12285397B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2470956A1 (en) | 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists | |
| JP2024517738A5 (cg-RX-API-DMAC10.html) | ||
| CL2012001056A1 (es) | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. | |
| CA2894417A1 (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2015522630A5 (cg-RX-API-DMAC10.html) | ||
| JP2023537921A5 (cg-RX-API-DMAC10.html) | ||
| JP2007520452A5 (cg-RX-API-DMAC10.html) | ||
| WO2000068229A3 (en) | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents | |
| US20220296553A1 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
| AR050463A1 (es) | Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer. | |
| IL292770A (en) | Formulations and dosages of polyethylene glycol-modified oricase | |
| WO2023081482A9 (en) | Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases | |
| MX2020013290A (es) | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. | |
| CN104955447A (zh) | 用于减轻口干燥症状和用于治疗口溃疡的局部口腔组合物 | |
| JP2013523628A5 (cg-RX-API-DMAC10.html) | ||
| BRPI0411702A (pt) | uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral | |
| JP2022028975A5 (cg-RX-API-DMAC10.html) | ||
| JP2022503733A5 (cg-RX-API-DMAC10.html) | ||
| JP2020536098A5 (cg-RX-API-DMAC10.html) | ||
| MX2023001572A (es) | Formas farmaceuticas sólidas de palbociclib. | |
| JP2020527138A5 (cg-RX-API-DMAC10.html) | ||
| MX2025012741A (es) | Composiciones farmaceuticas orales | |
| RU2014151156A (ru) | Налмефен для уменьшения потребления алкоголя у конкретных целевых популяций | |
| JP2018531961A5 (cg-RX-API-DMAC10.html) |